Tag: ADMA Biologics

July 8, 2019

ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®

ADMA Biologics NASDAQ:ADMA) has announced that the US Food and Drug Administration (FDA) has revoked the licenses for BIVIGAM and...
April 17, 2019

ADMA Biologics Granted US Patent for Treatment and Prevention of Pneumococcal Infections

ADMA Biologics (NASDAQ:ADMA) has announced it has been granted patent no. 10,259,865 from the US Patent and Trademark Office for...
December 24, 2018

Pharma Outlook 2019: Drug Pricing Dialogue Continues

During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry.
December 20, 2018

ADMA Biologics Provides Regulatory Update on BIVIGAM PAS Submissions

ADMA Biologics (NASDAQ:ADMA) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics...
October 11, 2018

ADMA Biologics Provides Regulatory Update for BIVIGAM

ADMA Biologics (NASDAQ:ADMA) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics...
October 3, 2018

ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center

ADMA Biologics (NASDAQ:ADMA) a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment...
July 26, 2018

ADMA Biologics Reports Successful Close-Out of its April 2018 FDA Compliance Inspection

ADMA Biologics (NASDAQ:ADMA) has announced that it has received formal notice from the US Food and Drug Administration (FDA) of...